Dimensional Fund Advisors’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-120,145
| Closed | -$481K | – | 3311 |
|
|
2025
Q2 | $481K | Sell |
120,145
-131,939
| -52% | -$327K | ﹤0.01% | 3001 |
|
|
2025
Q1 | $229K | Sell |
252,084
-252,586
| -50% | -$350K | ﹤0.01% | 3110 |
|
|
2024
Q4 | $1.4M | Buy |
504,670
+58,518
| +13% | +$223K | ﹤0.01% | 2864 |
|
|
2024
Q3 | $2.33M | Buy |
446,152
+66,088
| +17% | +$343K | ﹤0.01% | 2752 |
|
|
2024
Q2 | $1.7M | Buy |
380,064
+205,417
| +118% | +$996K | ﹤0.01% | 2800 |
|
|
2024
Q1 | $1.34M | Buy |
174,647
+110,962
| +174% | +$609K | ﹤0.01% | 2869 |
|
|
2023
Q4 | $272K | Buy |
63,685
+4,244
| +7% | +$15.1K | ﹤0.01% | 3148 |
|
|
2023
Q3 | $250K | Sell |
59,441
-23,755
| -29% | -$121K | ﹤0.01% | 3179 |
|
|
2023
Q2 | $463K | Buy |
83,196
+32,619
| +64% | +$193K | ﹤0.01% | 3079 |
|
|
2023
Q1 | $287K | Buy |
50,577
+28,370
| +128% | +$75K | ﹤0.01% | 3132 |
|
|
2022
Q4 | $24 | Sell |
22,207
-4,836
| -18% | -$8.45K | ﹤0.01% | 3447 |
|
|
2022
Q3 | $73K | Buy |
27,043
+13,956
| +107% | +$50.5K | ﹤0.01% | 3368 |
|
|
2022
Q2 | $63K | Buy |
+13,087
| New | +$56.9K | ﹤0.01% | 3375 |
|
Dimensional Fund Advisors's INZY Position: Q3 2025 in Review
Dimensional Fund Advisors sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 120,145 shares — an estimated $481K sold.
Dimensional Fund Advisors first reported a position in INZY in Q2 2022 and held it in 13 quarters. The position peaked at $2.33M in Q3 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Dimensional Fund Advisors reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Dimensional Fund Advisors sold 120,145 Inozyme Pharma shares in Q3 2025, an estimated $481K.
- Dimensional Fund Advisors first reported a position in Inozyme Pharma in Q2 2022 and held it in 13 quarters.
- Dimensional Fund Advisors's Inozyme Pharma position peaked at $2.33M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Dimensional Fund Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.